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Recent reports have identified a phenomenon by
which hypoxia shifts glutamine metabolism from
oxidation to reductive carboxylation.We now identify
the mechanism by which HIF-1 activation results in a
dramatic reduction in the activity of the key mito-
chondrial enzyme complex a ketoglutarate dehydro-
genase (aKGDH). HIF-1 activation promotes SIAH2
targeted ubiquitination and proteolysis of the
48 kDa splice variant of the E1 subunit of the aKGDH
complex (OGDH2). Knockdown of SIAH2 or mutation
of the ubiquitinated lysine residue on OGDH2
(336KA) reverses the hypoxic drop in aKGDHactivity,
stimulates glutamine oxidation, and reduces gluta-
mine-dependent lipid synthesis. 336KA OGDH2-
expressing cells require exogenous lipids or citrate
for growth in hypoxia in vitro and fail to grow as
model tumors in immunodeficient mice. Reversal of
hypoxic mitochondrial function may provide a target
for the development of next-generation anticancer
agents targeting tumor metabolism.
INTRODUCTION
Glutamine is the most abundant amino acid in blood and is
second only to glucose as a carbon source for energy production
and anabolic processes. Recently, glutamine was identified as
being essential for fuelling mitochondrial metabolism in rapidly
dividing cancer cells transformed with either c-MYC (Gao
et al., 2009; Wise et al., 2008) or Kirsten rat sarcoma viral
oncogene homolog (Son et al., 2013). Inhibiting glutamine meta-
bolism has been proposed as an anticancer therapy (Wise and
Thompson, 2010).
Mitochondrial glutamine metabolism can follow either oxida-
tive or reductive pathways (Holleran et al., 1995). Mitochondrial
utilization of glutamine begins with a two-step conversion of
glutamine to a ketoglutarate (aKG), typically by glutaminase
and glutamate dehydrogenase. aKG can be either oxidized by
aKG dehydrogenase (aKGDH) to succinate (standard tricarbox-
ylic acid [TCA] cycle reaction) or reductively carboxylated by iso-
citrate dehydrogenase (reverse TCA cycle) to isocitrate and thenCell Mcitrate. The reductive cycle has been shown to be favored in cells
where HIF-1a is stabilized (Metallo et al., 2012b; Wise et al.,
2011) or in cells with compromised electron transport capacity
(Mullen et al., 2012). Glutamine-derived citrate can be trans-
ported to the cytoplasm in order to generate acetyl CoA for
anabolic processes such as fatty acid synthesis (Gameiro
et al., 2013b; Metallo et al., 2012b).
aKGDH consists of E1 (oxogluterate dehydrogenase, OGDH),
E2 (dihydrolipoamide S-succinyltransferase, DLST), and E3 (di-
hydrolipoamide dehydrogenase, DLD) components that collec-
tively convert aKG to succinyl-CoA and nicotinamide adenine
dinucleotide (Patel and Harris, 1995). The three-enzyme (E1-
E2-E3) dehydrogenase complex structure is conserved in the
pyruvate dehydrogenase (PDH) and branched chain a-ketoacid
dehydrogenase complexes. PDH serves as the major entry point
for glucose-derived pyruvate into the mitochondrial TCA cycle
(Patel and Korotchkina, 2001). Recent work has found that
HIF1 activation inhibits PDH, which blocks glucose oxidation
(Kim et al., 2006; Papandreou et al., 2006). In humans,
there are three major splice variants of the OGDH gene, V1
(114 kDa), V2 (48 kDa), and V3 (114 kDa), although the functional
differences of these enzymes remain unreported.
Environmental hypoxia has a major effect on gene expression,
largely by the induction of the HIFa family of transcription factors
through protein stabilization (Epstein et al., 2001). However,
protein destabilization by hypoxia-regulated ubiquitination
(Vin˜as-Castells et al., 2010) or SUMOylation (Comerford et al.,
2003) has also been reported. The E3 ubiquitin ligase SIAH2
destabilizes several critical proteins in hypoxia (Qi et al., 2008).
In this work, we connect the crucial HIF-1 and SIAH2 regulatory
systems that control the metabolism of glutamine. Furthermore,
we show that this circuit is necessary for the growth of cells in
hypoxia and as model tumors.
RESULTS
HIF1 Stabilization Is Necessary and Sufficient to Reduce
Mitochondrial Glutamine Oxidation and aKGDH Activity
Hypoxia inhibits mitochondrial glucose oxidation (Denko, 2008;
Kim et al., 2006), so we asked whether it could also inhibit
glutamine oxidation. We found reduced mitochondrial oxygen
consumption (OCR) in the head and neck tumor cell line SAS
when they were treated with the HIF-stabilizing PHD inhibitor
DMOG. This decrease was detected in complete basal,
glucose-only, or glutamine-only media (Figure 1A). We alsoetabolism 19, 285–292, February 4, 2014 ª2014 Elsevier Inc. 285
Figure 1. Hypoxia Downregulates Glutamine Oxidation
(A) Mitochondrial oxygen consumption (OCR) in control and DMOG-treated SAS cells (500 mM, 16 hr). OCR was measured in basal DMEM without serum and
containing only 5 mM glucose, only 2 mM glutamine, or both as indicated.
(B) OCR in VHL-deficient RCC4 (constitutively active HIF1) and RCC4 cells with VHL reintroduced treated as in (A).
(C) OCR in empty vector SAS or shHIF1a SAS treated as in (A).
(D) Pyruvate dehydrogenase (PDH) enzyme activity in SAS, RCC4, and RCC4-VHL cells in control conditions or after 16 hr of 0.5% oxygen or 500 mM DMOG.
(E) aKGDH enzyme activity in SAS, RCC4, and RCC4-VHL cells treated as in (D).
(F) PDH activity in shHIF1a SAS cells treated as in (D).
(G) aKGDH activity in shHIF1a SAS cells treated as in (D).
Data represent three independent replicates ± SD. See also Figure S1.
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that have constitutive HIF1 activation show reduced glucose
and glutamine oxidation. Reintroduction of VHL into these
cells restores the hypoxic regulation of HIF-1, increases
normoxic mitochondrial OCR and restores its reduction in
response to DMOG (Figure 1B). These experiments determined
that HIF1a stabilization was sufficient to inhibit glutamine
oxidation. Next, we asked whether HIF1a was necessary
with the use of small hairpin RNA (shRNA) knockdown. Fig-
ure 1C shows that HIF1a is essential, given that its knockdown
in SAS cells blocked DMOG-dependent reduction in glutamine
oxidation.
Glutamine oxidation can be inhibited at any of the steps
involved in its uptake or conversion to aKG. However, the addi-
tion of aKG failed to restore mitochondrial OCR in DMOG
(Figure S1A available online), suggesting that the block is at
aKGDH itself. Therefore, we measured aKGDH enzyme activity
in SAS cells and found approximately 60% reduction upon HIF
stabilization, similar to the reduction in PDH activity (Figures
1D and 1E). RCC4 cells have low-level aKGDH activity that is
insensitive to hypoxia, and VHL reintroduction increases nor-
moxic aKGDH activity and restores its hypoxic response (Fig-
ure 1E). Similar HIF-responsive reductions in aKGDH and PDH286 Cell Metabolism 19, 285–292, February 4, 2014 ª2014 Elsevier Inactivity were seen in RKO colorectal cancer and MiaPaca2
pancreatic cancer cells (Figures S1B and S1C). However, in
the SAS cells with shRNA to HIF1a, there was greatly reduced
decrease in PDH (Figure 1F) and no decrease in aKGDH activity
(Figure 1F). There was very modest hypoxic regulation of gluta-
mate dehydrogenase (Figure S1D), NADP-dependent isocitrate
dehydrogenase (Figure S1E), or carboxylase (Figure S1F), sug-
gesting that these activities were not rate limiting.
OGDH2 Is Marked for Proteolysis in Hypoxia by SIAH2-
Dependent Ubiquitination
HIF-1 control of aKGDH suggested that there is a HIF-1-respon-
sive gene whose product interacts with aKGDH in order to inhibit
it. However, gene expression studies have not identified such a
gene. Therefore, we examined the aKGDH protein subunits.
There was a modest hypoxia-dependent decrease in the level
of E2 (DSLT) but no change in E3 (DLD) or in the larger splice
variants of OGDH (114 kDa proteins 1 and 3). However, we found
that hypoxia caused the complete loss of the small protein
derived from splice variant OGDH2 (Figure 2A). Treatment of
hypoxic SAS cells with the proteasome inhibitor MG132 restored
OGDH2 protein levels (Figure 2A). Similarly, hypoxia specifically
reduced OGDH2 in RKO and MiaPaca2 cells, and RCC4 cellsc.
Figure 2. SIAH2 E3 Ligase Is Responsible
for OGDH2 Protein Degradation after HIF1
Stabilization
(A) Western blot of SAS protein extracts from
control, 0.5% O2 conditions, and 0.5% O2 with
10 mM MG132, 50 mM VitK3, or 10 mM DUBI and
MG132 as indicated.
(B) aKGDH activity in SAS cells treated with either
500 mM DMOG or DMOG in combination with
10 mM MG132 or 50 mM VitK3.
(C) Western blot analysis of the indicted proteins
in SAS, RCC4, and RCC4-VHL cells with and
without shRNA-SIAH2 as indicated cultured in
normoxia or 16 hr 0.5% oxygen.
(D) aKGDH activity in control and shRNA-SIAH2
SAS, RCC4, and RCC4-VHL cells ± 16 hr 500 mM
DMOG.
(E) Mitochondrial OCR in control and shRNA-
SIAH2 SAS, RCC4, and RCC4-VHL cells ± 16 hr
500 mM DMOG measured in basal, serum-free
media containing only glutamine.
Data from (B), (D), and (E) are two independent
experiments in triplicate ± SD. See also Figure S2.
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MG132 (Figure S2A).
aKGDH E2 has been reported to be marked for proteolysis by
the E3 ubiquitin ligase SIAH2 upon mitochondrial disruption (Ha-
belhah et al., 2004); therefore, we examined whether SIAH2
could be responsible for the hypoxic destruction of OGDH2.
We found that the SIAH2 inhibitor Vitamin K3 (Shah et al.,
2009) could also restore OGDH2 protein (Figure 2A). Further-
more, treatment of hypoxic cells with both MG132 and the deu-
biquitinating enzyme inhibitor nsc632839 resulted in the appear-
ance of variant of OGDH2 7kDa larger, suggesting the addition of
ubiquitin (Figure 2B). Larger, polyubiquitinated species could
not be detected because of nonspecific antibody reactivity at
60 kDa. We also found that MG132 or VitK3 could restore hypox-
ic aKGDH activity (Figure 2B). These treatments had no effect on
OGDH2 protein levels in normoxic conditions (Figure S2B).Cell Metabolism 19, 285–292In order to genetically connect
SIAH2 ubiquitination to HIF-dependent
decrease of OGDH2 protein, we reduced
SIAH2 protein with stable shRNA in SAS,
RCC4, and RCC4VHL cells (Figure 2C,
top row). This treatment decreased both
the baseline and hypoxia-inducible
SIAH2 protein and blocked HIF-depen-
dent reduction of OGDH2 and the
SIAH2 target protein PHD3 (Nakayama
et al., 2004). This genetic manipulation
also blocked the HIF-dependent
decrease in aKGDH activity and mito-
chondrial OCR in the SAS cells (Figures
2D and 2E). We also found that stable
knockdown of SIAH2 in VHL-deficient
RCC4 cells resulted in increased nor-
moxic OGDH2 protein levels, aKGDH
activity, and mitochondrial OCR, which
were all insensitive to hypoxia or DMOG(Figures 2C–2E). Finally, SIAH2 knockdown in the RCC4 VHL
cells resulted in no change in normoxic OGDH2protein or activity
but blocked the reduction of these measures in DMOG (Figures
2C–2E).
HIF-Dependent Change in Glutamine Metabolism
Enhances the Growth of Tumors In Vivo
To determine the functional consequence of hypoxic SIAH2
dependent proteolysis of OGDH2, we needed to specifically
block it while allowing SIAH2 to mark other proteins (Nakayama
et al., 2009). Therefore, we identified the specific ubiquitinated
lysine residue on OGDH2 using mass spectrometry so we could
mutate it and block the SIAH2-dependent destruction. We
immunoprecipitated FLAG-OGDH2 from hypoxic cells treated
with MG132 and DUBI and analyzed the precipitate at the Ohio
State University Comprehensive Cancer Center proteomic core, February 4, 2014 ª2014 Elsevier Inc. 287
Figure 3. Hypoxia-Resistant aKGDH Activ-
ity Is Not Compatible with Tumor Growth
(A) Different splice variants of OGDH. OGDH 1 and
OGHD3 are 99% identical except at amino acid
positions 153–169 (represented by the inverted
triangle). OGDH2 is identical toOGDH1 until amino
acid 403.
(B) Western blot of lysates from SAS cells stably
expressing empty vector, FLAG-WT OGDH2, and
FLAG-336KA OGDH2 exposed to normoxia or
0.5% oxygen for 16 hr. Lysates were probed for
proteins as indicated. Note that both anti-FLAG
and anti-OGDH2 show OGDH2 336KA that is
resistant to hypoxic degradation.
(C) aKGDH activity in SAS cell lines described in
(B) treated with either control, 16 hr 500 mM
DMOG, or 0.5% oxygen.
(D) Mitochondrial OCR in SAS cell lines described
in (B) treated with either control, 500 mMDMOG, or
0.5% oxygen and measured in glutamine-only
media.
(E) Tumor volume of SAS cells expressing empty
vector, OGDH-WT, and OGDH-336KA grown in
nude mice (n = 8–10 per group). Statistically
significant growth differences exist between all
three groups.
(F) Western blot analysis of lysates of tumors
harvested after growth as described in (E). Note
the decrease in markers of proliferation as tumors
grow more slowly.
Data from (C) and (D) are mean ± SD and tumor
volumes are mean ± SE. See also Figure S3 and
Table S1.
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with OGDH2, including the E2 subunit of aKGDH (DSLT) and
the E1b subunit of PDH (Table S1). One peptide of OGDH2
was ubiquitinated at residue lysine 336 (Figure S2C). We
converted lysine 336 to alanine by site-directed mutagenesis
and stably introduced the wild-type (WT) or mutant proteins
into SAS cells. The modified protein showed significant resis-
tance to hypoxic degradation (Figure 3B, second and third
rows) and did show high-molecular-weight polyubiquitinated
species when treated with hypoxia, MG132, and DUBI (Fig-
ure S3A). The cells expressing the 336KA OGDH2 protein were
also resistant to HIF-dependent reduction of aKGDH activity
(Figure 3C) and OCR (Figure 3D). 336KA OGDH2 showed similar
function when introduced into RKO and MiaPaca2 cells (Figures
S3B–S3I).
We could then determine the importance of reductive gluta-
mine metabolism for the growth of model tumors. Cells express-
ing either WT or hypoxia-resistant OGDH2 were injected into
immunodeficient mice for growth as tumors. Overexpression of
the WT protein had a modest inhibitory effect on tumor growth
(Figure 3E), possibly because high-level expression resulted in288 Cell Metabolism 19, 285–292, February 4, 2014 ª2014 Elsevier Inc.incomplete degradation (Figures 3B
and 3F). Expression of the hypoxia-resis-
tant 336KA protein had a profound inhib-
itory effect (Figure 3E). Although both
OGDH2-modified cell line tumors grew
slower than the parental tumors, the cellsexpressing 336KA OGDH2 grew significantly slower than the
cells expressing WT OGDH2. Similar tumor growth inhibition of
the two proteins was seen in RKO and MiaPaca2 cells (Figures
S3B–S3I). Analysis of lysates from these tumors showed that
WT FLAG-OGDH2 was expressed at intermediate levels in vivo,
whereas 336KA FLAG-OGDH2 was expressed at much higher
levels (Figures 3F, S3E, and S3I). Furthermore, analysis of the
tumor lysates for markers of proliferation (Ki67 and cyclin D) indi-
cated that there was reduced proliferation in the336KA OGDH2
tumors. There was no increase in the apoptotic marker, cleaved
caspase 3. These results suggest that reductive carboxylation of
glutamine is necessary for the proliferation of tumor cells in vivo.
Cellular Growth in Hypoxia Requires Glutamine-Derived
Lipid Production
The tumors expressing 336KA OGDH2 appeared to have
reduced proliferation, so we examined the effect of forced gluta-
mine oxidation on the proliferation of tumor cells in vitro. Reduc-
tive carboxylation of glutamine in hypoxia has been proposed to
be a mechanism for generating citrate for lipid synthesis when
glucose entry into the TCA cycle is reduced (Le et al., 2012;
Figure 4. OGDH 336KA Inhibits Cell Growth under Hypoxia by Reducing Glutamine-Derived Lipid Production
(A) Relative hypoxic proliferation of SAS, RCC4, and RCC4VHL cells grown for 72 hr in the indicated media presented as a percentage of normoxic growth.
Hypoxic growth requires either glutamine (2 mM) or glutamine derivatives aKG (2 mM) or citrate (2 mM).
(B) Hexane-soluble lipids derived from a 1 hr pulse of 0.5 mCi 14C-glutamine in SAS cells expressing either empty vector or OGDH2-336KA grown for 16 hr in
normoxia or hypoxia.
(C) Hexane-soluble lipids derived from a 1 hr pulse of 0.5 mCi 14C-glucose in SAS cells as described in (B).
(D) Relative hypoxic proliferation of SAS cells expressing empty vector or 336KA- OGDH2 after 72 hr in basal glutamine-containing media and 10% charcoal-
stripped serum supplemented with either 2 mM citrate or 2 mM aKG. Note that WT cells have maximal hypoxic proliferation with glutamine, but 336KA-OGDH2-
expressing cells require citrate.
(legend continued on next page)
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Hypoxia Downregulates aKGDH ActivityMetallo et al., 2012a; Wise et al., 2011). Removal of glutamine
from the media causes significant growth inhibition in hypoxia,
which can be rescued with the addition of aKG (Wise et al.,
2011) or citrate (Figure 4A). Therefore, we directly measured
the incorporation of either glucose or glutamine into newly
synthesized fatty acids with 14C-labeled precursors. Cells
expressing either empty vector or 336KA OGDH2 were treated
with hypoxia and pulsed with radio-labeled glucose or gluta-
mine. Glutamine uptake was slightly reduced by hypoxia in all
lines, whereas glucose uptake was increased (Figures S4A–
S4D). Fatty acid production was measured by determining
hexane-extractable counts from the pulsed cells. Both lines
showed hypoxic decrease in glucose incorporation into lipids
(Figure 4C). However, therewas a specific reduction in glutamine
incorporation into lipids in the 336KA-OGDH2-expressing cells.
Glutamine-derived lipids were increased by hypoxia in empty
vector cells but were further reduced in 336KA cells (Figure 4B).
Consistent results were observed in RCC4 and RCC4VHL cells
(Figures S4E and S4F).
The 336KA OGDH2 cells allowed us to determine whether
the inability to generate lipids from glutamine would inhibit
hypoxic proliferation in vitro. We found that the 336KA
OGDH2-expressing cells grew as fast as the empty vector cells
in normoxia but had a reduced growth rate in hypoxia, even in
complete media with glutamine and 10% charcoal stripped
serum (to remove the serum lipids) (Figure 4D). This 336KA-
dependent growth defect was due to an inability to produce
mitochondrial metabolites, given that hypoxic growth of these
cells could be rescued by addition of exogenous citrate but not
exogenous aKG (which is simply oxidized instead of being
used to make citrate) (Figure 4D). To establish that the growth
defect was due to a lack of citrate to produce lipids, we added
the desaturated lysophospholipid (C18:1) that is rapidly taken
up by cells (Kamphorst et al., 2013). This lipid could rescue the
glutamine-dependent growth of WT OGDH2 cells and the cit-
rate-dependent growth of the 336KA OGDH2-expressing cells.
The saturated lysophospholipid (C24:0) that is poorly taken up
by cells could not rescue either cell lines (Figures 4E and S4G).
DISCUSSION
Microenvironmental hypoxia is a significant stress that produces
compensatory metabolic changes in tumor cells. The cell con-
serves oxygen by reducing its use for mitochondrial energy
production. However, reduction of TCA cycle reactions leads
to a reduced supply of mitochondrial intermediates. Under hyp-
oxic pressure, cells use alternative fuels such as glutamine to
generate citrate and support proliferation (Figure 4F). Cells can
use this compensation until the oxygen level becomes too low,
at which point they die (Papandreou et al., 2005).
Recent publications have described how low levels of intracel-
lular citrate and high levels of aKG are associated with HIF-
dependent reductive carboxylation of glutamine (Fendt et al.,
2013; Gameiro et al., 2013a). These elegant tracer studies are(E) Relative hypoxic proliferation of SAS cells described in (D) in basal media wit
pholipid rescues the glutamine dependence of the WT OGDH2 cells and the citr
(F) A model illustrating how hypoxic degradation of OGDH2 shifts the fate of aKG
Data from panels (A)–(E) represents mean ± SD. See also Figure S4.
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findings. Their conclusions focused on the changes in the me-
tabolites during hypoxia but did not identify how these changes
occurred. We now propose that hypoxia causes a decrease in
glucose-derived citrate because of decreased PDH activity
and also increases aKG levels because of decreased aKGDH
activity. These changes in substrate concentrations drive the
reverse reaction at isocitrate dehydrogenase.
The biochemical regulation of the mammalian aKGDH
complex is understudied. The E1 component of the related
PDH contains two proteins, the a protein with a thiamine pyro-
phosphate binding domain (TBD) and the b protein with a trans-
ketolase-like domain (TK). In PDH, the E1 subunit functions as a
heterotetramer of a2b2. The full-length aKGDH E1 (variants 1 or
3) OGDH protein contains both a TBD and TK domain and func-
tions as a homodimer. The smaller OGDH variant 2 contains just
the TBD. However, PDHE1b copurified with OGDH2 (Table S1).
This suggests that OGDH2 can function in the aKGDH complex
by adding transketolase activity with the use of the PDH version
found in the E1b enzyme. Careful biochemical purification and
analysis will be needed to determine whether this is indeed the
case.
The mechanism by which OGDH2 is specifically degraded
in hypoxia is interesting, given that lysine 336 is conserved on
the full-length OGDH1 and OGDH3. There may be variable
accessibility to the lysine based on the 3D structure of the whole
versus half protein or by function of its interactions with PDH
E1b. It is also not yet clear how an intramitochondrial protein
could be degraded by the cytoplasmic proteasome, although
recent work has shown that such a mechanism exists (Azzu
and Brand, 2010).
Fatty acid desaturation and cholesterol synthesis require
molecular oxygen as an enzymatic substrate, indicating why
these processes should be regulated under hypoxia. Recent
work has shown that hypoxic cells preferentially take up unsatu-
rated lysophospholipids from the growth media, and the level of
activity of the sterol desaturase is also downregulated by hypox-
ia (Kamphorst et al., 2013). Here, we show that de novo lipogen-
esis is also required for the growth of cells in hypoxia in vitro and
in the hypoxia that exists within the tumor microenvironment.
Glutamine appears to play a crucial role in hypoxic lipogenesis
because glucose flux into the mitochondria is limited by reduced
PDH activity. However, it is not apparent why blocking the
hypoxic downregulation of PDH (and stimulate glucose flux
into themitochondria) can also block the growth ofmodel tumors
(Hitosugi et al., 2011; McFate et al., 2008).
EXPERIMENTAL PROCEDURES
Cells
MiaPaca2 pancreatic cancer and RKO colorectal cancer cells were from
ATCC. SAS head and neck cancer, RCC4 renal cancer, and RCC4-VHL cells
were gifts from Q. Le and A. Giaccia of Stanford University. All cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS), 25 mM glucose, and 4mM L-glutamine; unless statedh 10% charcoal-stripped serum. Supplementation with absorbable lysophos-
ate dependence of the 336KA-OGDH2-expressing cells.
from energy production to the production of lipids.
c.
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Hypoxia Downregulates aKGDH Activityotherwise, metabolic experiments were conducted in 5 mM glucose. Hypoxia
(0.5% oxygen) was generated in a HypOxygen H35 workstation. Cells were
regularly tested for mycoplasma. For lipid-dependent experiments, DMEM
was supplemented with 10% charcoal-stripped FBS (Invitrogen). For tumor
growth, 5 3 106 cells were injected subcutaneously into the flank of nude
mice, the growth of tumors was monitored with calipers, and volume was
calculated by w2 3 l 3 0.52.
Dehydrogenase Assay
For aKGDH activity assay, 104 treated cells were permeabilized with 0.5%
Triton X-100 and incubated 1 mM MgCl2, 0.1 mM CaCl2, 0.05 mM EDTA,
0.2% Triton X-100, 0.3 mM ThDP, rotenone, 3 mM aKG, 3 mM NAD+, 1 mM
CoA, 0.75 mM nitroblue tetrazolium, and 0.05 mM phenazine methosulfate
in 50 mM Tris (pH 7.6) at 37C for 40 min. Then, cells were solubilized in
10% SDS and 0.01N HCl overnight. Optical density at 570 was determined
(Molecular Devices). Slight modifications were made for PDH, isocitrate dehy-
drogenase (IDH), and GDH activities (see the Supplemental Information).
Oxygen Consumption Rate
1–23 104 cells were plated in 96-well Seahorse Assay plates. The next morn-
ing, culture media was replaced with bicarbonate-free DMEM with or without
glucose or glutamine, and oxygen consumption rate was measured.
Mass Spectrometry
Carboxy-tagged FLAG-OGDH2 expression plasmid was purchased from
Origene. FLAG-OGDHV2 cells were cultured for 16 hr in 0.5% oxygen and
Mg132 and DUBI for 3 hr. Precipitated FLAG-OGDH2 was analyzed on a
Thermo Scientific LTQ Orbitrap mass spectrometer equipped with a micro-
spray source (Michrom Bioresources), data collected were searched by
Mascot Daemon (Matrix Science). Modifications identified were methionine
oxidation (variable), deamidation (variable), ubiquitination (variable), and car-
bamidomethyl cysteine (fixed).
Lipid Synthesis
53 104 cells were plated in 12-well plates in 0.5% oxygen or 0.5 mMDMOG in
DMEM (5 mM glucose and 1 mM glutamine), and, 16 hr later, 0.5 mCi 14C-L-
glutamine (0.5 mCi/mM) or glucose (0.1 mCi/mM) was added for 1 hr. Cells
were rinsed with PBS, and lipids were extracted with 500 ul of hexane:isopro-
panol (3:1) for 30 min. Total extractable counts are reported.
Statistics
Statistical comparisons were made with a two-tailed Student’s t test,
and values are indicated with *p < 0.05, > 0.01; ** p < 0.01, > 0.001; ***p <
0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2013.11.022.
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